P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Durvalumab with bacillus Calmette–Guérin therapy for high-risk non-muscle-invasive bladder cancer: expanded efficacy and safety analyses from POTOMAC
Friday, May 15, 2026 10:30 AM to 10:40 AM · 10 min. (America/New_York)
Hall D
Detail
Registered attendees
Eugene Pietzak
Urologic OncologistMemorial Sloan Kettering Cancer Center
Henri Morgan
UrologistHospital das Clínicas, Faculty of Medicine, University of São Paulo (HCFMUSP)
Ignacio Tobia Gonzalez
Associate Profesor Urology Department Hospital Italiano de Buenos AiresLatin Ametrican Renal Cancer Group